Please assess the completion status of the following clinical trial:

Trial Title: Phase I - Pharmacokinetic Comparability Study in Healthy Male Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Males aged 18-55 yrs. (inclusive)~* BMI: 19.0 to 30.0 kg/m2 (inclusive)~* Weight: ≥ 60kg and ≤100kg~* Subjects should be willing to use adequate contraception and not donate sperm from admission to clinical research center until 6 months post dosing.~* All intermittent medications should have be stopped at least 14days prior to admission to the clinical research center.~* All intermittent non topical medication must be stopped at least 30days prior to admission to the clinical research center.~* Ability and willingness to abstain from ETOH 48hrs prior to admission to the clinical research center.~* Medical history without significant findings per the PI~* Resting supine systolic BP of ≤140mmHg and diastolic BP of ≤90mmHg~* ECGs (via 12 lead) showing NCS findings per PI~* All clinical laboratory tests of blood and urine, WNL and/or without clinically significant findings~* Willing/able to sign ICF~* Normal bowel habits~* Negative medical history regarding fecal blood positivity~* Normal and/or NCS spot protein/creatinine (PCR) ratio.~Exclusion Criteria:~* Previous participation in the current study~* History of prior exposure to bevacizumab~* Evidence of clinically significant findings~* Cognitive and / or mentally impaired handicaps that would affect ability to make an informed consent and/or remain compliant to the requirements of this trial.~* History of relevant drug and/or food related allergies.~* History of or known hypersensitivity to bevacizumab or other recombinant human or humanized antibodies or inactive ingredients.~* Tobacco product use w/I 1 yr. prior to drug administration.~* History of ETOH and or drug abuse/addiction~* Positive urine drug and ETOH screen for opiates, methadone, cocaine, amphetamines including XTC, cannabinoids, barbiturates, benzodiazepines, tricyclic antidepressants and ETOH.~* Average intake of more than 24 units of ETOH / wk. (1 unit of ETOH equals \~250mL of beer, 100mL of wine or 35mL of spirits).~* Consumption of any foods containing poppy seeds w/I 48 hrs. prior to screening and admission to the clinical research center~* Positive screen for Hepatitis B surface antigen (HBsAg), anti-hepatitis C virus (HCV) antibodies or anti-human immunodeficiency virus (HIV) 1 and 2 antibodies.~* Participation in a drug study w/I 60days or 5 half-lives of the previous drug.~* Participation in more than 3 other drug studies in the 10months prior to drug administration in the current protocol.~* Donation or loss of more than 100mL of blood w/I 60days prior to drug administration. Donation or loss of more than 1.5liters of blood w/I the 10months prior to drug administration.~* Strenuous exercise w/I 96 hrs. Prior to admission to the clinical research center.~* Significant or acute illness w/I 5days prior to drug administration that may impact safety assessments per the judgement of the PI.~* Unsuitable veins for infusion and/or venepuncture~* Surgery including surgery with suturing via a dental procedure or would dehiscence w/I 28days of dosing. Any planned surgery or dental procedures during the study and for at least 30days after follow up.~* Presence of a non-healing wound or fracture.~* History of bleeding disorders~* History of thromboembolic conditions~* History of gastrointestinal perforations or any fistulae.~* History of orthostatic hypotension, fainting spells, blackouts for any reasons.~* History of hypertension~* Medically significant dental disease or dental neglect with signs and or symptoms of local or systemic infection that would likely require a dental procedure during the course of study.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- MYL-1402O (Type: EXPERIMENTAL): MYL-1402O (bevacizumab), single 1mg/kg i.v. infusion over 90 minutes.
- US Marketed Avastin (R) (Type: ACTIVE_COMPARATOR): US Marketed Avastin(R) (bevacizumab), single 1mg/kg i.v. infusion over 90 minutes.
- EU Marketed Avastin(R) (Type: ACTIVE_COMPARATOR): EU Marketed Avastin(R) (bevacizumab), single 1mg/kg i.v. infusion over 90 minutes.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete